Addex Therapeutics enters collaboration with Sinntaxis AB

Addex Therapeutics (ADXN) announced that it has entered into an option- and collaboration agreement with Sinntaxis AB for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 inhibitors for the treatment of brain injury recovery. The agreement also includes a research collaboration under which the Sinntaxis team will complete evaluation of Addex’s dipraglurant, an orally active mGlu5 negative allosteric modulator, for the treatment of brain injury recovery. Under the terms of the agreement, Addex will pay Sinntaxis an undisclosed option fee to obtain an exclusive license to access intellectual property rights that Sinntaxis holds covering the use of mGlu5 NAMs to improve recovery of function in patients suffering from brain damage or injury as the result of a stroke or other brain trauma. The agreement also includes a collaboration under which Sinntaxis will execute a research plan to complete the preclinical evaluation and contribute expertise in designing clinical plans.